Clinical trials have shown that drugs that inhibit sodium-glucose cotransporter 2 (SGLT2), which is expressed in PTEC, improve the prognosis of DKD, lending credence to this theory [2,3,4,5,6,7,8,9,10,11]. Here, SLC5A2 is linked to diabetic kidney disease.